Advertisement

Life Sciences

FDA OKs rectal cancer immunotherapy | Compounded GLP-1s recalled nationwide | FDA approves 1st-of-its-kind hepatitis B drug | GLP-1s may protect patients after surgery | Roche inks potential $15B cancer deal

HHS sends peptide compounding plan to the White House for review. October 21, 2026 1. FDA approves surgery-sparing immunotherapy for rectal cancer Full story 2. Compounded GLP-1 injections recalled nationwide: 4 notes Full story 3. Between visits, care plans quietly…

By: Sachin Waghe

2 deaths reported after people took purported retatrutide | 5 new FDA approvals | HHS to allow unapproved peptide sales | FDA flags 4 deaths as potential schizophrenia drug safety signal | Which patients benefit most from GLP-1s?

CVS to pay $315M over opioid prescriptions, ‘trinity’ drug combos. October 14, 2026 1. 2 deaths reported to FDA after people took products claiming to be Lilly weight loss drug Full story 2. 5 new FDA approvals to know Full…

By: Nikhil Gaikwad

FDA panel backs 1st multi-cancer blood test | Off-label GLP-1 use jumps fifteenfold | Eli Lilly's weekly insulin injection approved | FDA flags sterility concerns at major GLP-1 compounder | Novo plans 5 blockbuster drugs

Health system pharmacy keeps 96% of GLP-1 patients on therapy. September 30, 2026 1. FDA panel backs first multi-cancer blood test: What to know Full story 2. Off-label GLP-1 use jumped fifteenfold in 4 years: 5 notes Full story 3. Payer contract…

By: Nikhil Gaikwad

Lung cancer drug doubles survival | GLP-1s and blindness: 6 notes | Trump calls for split vaccine doses | Medicare's GLP-1 program exceeding expectations | 2 countries supply 90% of US drug ingredient filings

Plus: What to know from the FDA’s hearing on psychedelic drugs. September 23, 2026 1. Lung cancer drug doubles survival in trial: What to know Full story 2. Trump calls for vaccine manufacturers to split up doses, repeats autism claim…

By: Nikhil Gaikwad
Advertisement

Can an AI drug slow aging? | Mayo Clinic, Thermo Fisher debut disease detection joint venture | Wegovy cuts child obesity rates | Lung disease drug posts record 56% reduction | 100% of cancer centers report at least 1 drug shortage

Plus: Novo Nordisk secures injunction over Ozempic, Wegovy claims. September 16, 2026 1. Can an AI-generated drug slow aging? 6 notes Full story 2. Mayo Clinic, Thermo Fisher debut disease detection joint venture Full story 3. Reimbursement complexity threatens pharmacy margins.…

By: Nikhil Gaikwad

Pancreatic cancer drug shrinks tumors in 33% of patients | FDA warns on compounded GLP-1s: 1,700+ reports | FDA OKs 1st-of-its-kind breast cancer drug | Novartis pauses CAR-T trials after 3 deaths | GLP-1 use rising fast among children

Plus: What’s ahead for 13 weight-loss drugs in the pipeline. September 9, 2026 1. FDA warns clinicians on compounded GLP-1s amid 1,700+ safety reports Full story 2. Pancreatic cancer drug shrank tumors for 1 in 3 lung cancer patients: Early…

By: Nikhil Gaikwad

Pancreatic cancer drug nearly doubles survival time | Mounjaro cleared to reduce cardiovascular risk | GLP-1s and breast cancer: 5 notes | FDA approves 1st-of-its-kind drug for rare blood disorder | Ifosfamide shortage turns critical

Also inside: AstraZeneca halts a lung cancer drug trial. September 2, 2026 1. FDA approves pancreatic cancer drug that nearly doubles survival time Full story 2. FDA expands Mounjaro approval to reduce cardiovascular risk Full story 3. A patient’s financial instability can…

By: Nikhil Gaikwad

Regenxbio trial paused again after spine masses found | FDA OKs first-line treatments for 3 cancers | Lilly, Novo Nordisk combat GLP-1 copycats | Thyroid drug recalled nationwide | 6 new FDA approved drugs to know

Also inside: which drug categories have the most active shortages right now. August 26, 2026 1. FDA pauses Regenxbio trial again after spine masses found in 5 patients Full story 2. FDA approves new first-line treatments for 3 cancers Full…

By: Nikhil Gaikwad

FDA rejects rival to Novartis cancer therapy | Prader-Willi drug faces concerns after 7 deaths | How AstraZeneca's $400B deal fell apart | Melanoma vaccine clears phase 3 trial | 8 GLP-1 updates to know

Novartis’ rival gets rejected, AstraZeneca’s deal collapses and a new myeloma drug clears the FDA. August 19, 2026 1. Clinicians flag safety concerns for Prader-Willi drug after 7 deaths Full story 2. FDA rejects cancer therapy positioned to rival Novartis…

By: Nikhil Gaikwad
Advertisement